Core Insights - Marubi Biotechnology (603983) has successfully obtained a patent for a cosmetic product with whitening and sunscreen functions, utilizing a unique preparation method [1] Group 1: Patent and Innovation - The patent combines chemical and physical sunscreen agents through a novel compounding technology, proposing a cosmetic product that offers both whitening and sun protection [1] - Marubi's R&D team has developed the Namoletar porous encapsulation technology, which uses nanoscale porous silica to effectively encapsulate active sunscreen ingredients, enhancing sun protection while reducing skin penetration of the sunscreen agents [1] - This technology allows for the development of a dual-function product that integrates sun protection and skin care, marking a significant innovation in the industry [1] Group 2: Recent Developments - In the third quarter of this year, Marubi added 10 new national invention patents, focusing on core functions such as whitening sunscreen, eye health, and anti-inflammatory skincare [1] - The continuous acquisition of patents strengthens Marubi's technological barriers and empowers high-quality development in the industry through robust innovation [1]

Core Viewpoint - Guangdong Marubi Biotechnology Co., Ltd. has been issued an administrative regulatory decision by the Guangdong Securities Regulatory Commission due to irregularities in financial accounting, fundraising management, and disclosure practices [2][4][6]. Financial Accounting Irregularities - The company has been found to have inaccurate revenue accounting, failing to estimate return rates based on actual sales returns and including non-actual sales orders in revenue [4]. - There were inaccuracies in the accounting of construction in progress, with the company not timely estimating unbilled construction payments and failing to transfer assets to fixed assets upon completion [4]. - Errors in accounting classifications were noted, such as misreporting funds held in third-party payment platforms as accounts receivable and misclassifying unrelated consulting fees as research and development expenses [4]. Fundraising Management and Disclosure Issues - The company improperly used fundraising and self-owned funds for the construction of its headquarters without separating the accounting for fundraising projects from non-fundraising projects [5]. - Adjustments to fundraising projects were not timely reviewed and disclosed, leading to discrepancies between reported project progress and actual status [5]. - The company failed to disclose relevant information regarding cash management of fundraising, including returns on financial products and investment details [5]. Regulatory Actions - The chairman, board secretary, and financial director of the company have been held primarily responsible for the violations and have received warning letters from the regulatory authority [6]. Financial Statement Corrections - The company announced corrections to its financial statements for the first half of 2025, revealing inflated figures in various financial metrics, including an increase in operating income by 4.5468 million and net profit by 11.3297 million [7][10]. - The corrected balance sheet showed an overstatement of construction in progress by 568 million and underreported fixed assets and investment properties by 375 million and 183 million, respectively [10]. Recent Financial Performance - For the third quarter of 2025, the company reported operating revenue of 2.45 billion, a year-on-year increase of 25.5%, while net profit attributable to shareholders was 244 million, up 2.1% year-on-year [10].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported strong performance in Q3 2025, with a year-on-year revenue increase of 25.5% to 2.45 billion yuan and a net profit increase of 2.1% to 240 million yuan. Q3 revenue reached 690 million yuan, up 14.3%, and net profit was 70 million yuan, up 11.6% [3][4] - The company maintains its profit forecast, expecting net profits of 400 million yuan, 523 million yuan, and 667 million yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 1.00, 1.30, and 1.66 yuan [3][4] Financial Performance Summary - For Q3 2025, the company achieved revenue of 690 million yuan, with a gross margin of 75.7% (up 1.2 percentage points) and a net margin of 10.5% (up 0.03 percentage points) [4] - The revenue breakdown for Q3 2025 shows eye care products generating 150 million yuan (up 20.1%), skincare products 310 million yuan (up 42.0%), cleansing products 70 million yuan (up 23.1%), and beauty products 150 million yuan (down 26.7%) [4] - The average selling prices for Q3 2025 increased significantly, with eye care products up 52.8% and skincare products up 4.5% [4] Financial Projections - The company forecasts revenue growth from 2.226 billion yuan in 2023 to 5.906 billion yuan in 2027, with a compound annual growth rate (CAGR) of 28.5% to 21.7% [6][8] - The projected net profit is expected to grow from 259 million yuan in 2023 to 667 million yuan in 2027, reflecting a CAGR of 48.9% to 27.6% [6][8] - The gross margin is projected to improve from 70.7% in 2023 to 74.8% in 2027, while the net margin is expected to stabilize around 11.3% by 2027 [6][8] Market Positioning - The company continues to lead the domestic eye care market and has launched new products targeting the mid-to-high-end market, such as the "Perfect Collagen Eye Cream" [5] - The company is enhancing its online and offline presence, with significant sales during promotional events like Double 11, achieving over 4 million units sold in the first four hours of a live broadcast [5]

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company reported a revenue of 2.45 billion yuan for Q1-Q3 2025, representing a year-on-year increase of 25.51%, with a net profit of 244 million yuan, up 2.13% year-on-year [2] - The company continues to optimize its product structure, with strong performance from key products, particularly in the eye care and skincare categories [3] - The gross profit margin for Q1-Q3 2025 was 74.91%, showing a slight increase, while the net profit margin was 9.95%, reflecting a decrease [4] Revenue Summary - For Q3 2025, the company achieved a revenue of 686 million yuan, a year-on-year increase of 14.28% [2] - Breakdown of revenue by product category for Q3 2025: - Eye care: 149 million yuan (+20.10%) - Skincare: 306 million yuan (+42.05%) - Cleansing: 67 million yuan (+23.06%) - Beauty: 148 million yuan (-26.71%) - Other: 16 million yuan (+285.46%) [3] Profitability Summary - The company’s gross profit margin for Q3 2025 was 75.72%, an increase of 1.20 percentage points year-on-year [4] - The net profit margin for Q3 2025 was 10.13%, a slight decrease of 0.24 percentage points year-on-year [4] - The company plans to enhance cost control and stabilize expenses to improve profitability [5] Expense Summary - The operating expense ratio for Q1-Q3 2025 was 63.77%, an increase of 3.12 percentage points year-on-year [5] - For Q3 2025, the operating expense ratio rose to 69.04%, with increases in sales and management expenses attributed to heightened competition and increased team size [5] Investment Recommendations - The company is expected to achieve synchronized growth in revenue and profit due to brand strengthening and operational efficiency improvements [6] - Revised revenue forecasts for 2025-2027 are 3.68 billion, 4.48 billion, and 5.42 billion yuan respectively, with net profits of 397 million, 493 million, and 631 million yuan [6] - The estimated EPS for 2025-2027 is projected to be 0.99, 1.23, and 1.57 yuan, with corresponding PE ratios of 35, 28, and 22 times [6]

Market Overview - The cosmetics sector experienced a decline of 0.58% on October 31, with Jiaheng Jiahua leading the drop [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Individual Stock Performance - Notable gainers included: - Qingsong Co., Ltd. (300132) with a closing price of 7.23, up 5.39% [1] - Lafang Jiahua (603630) at 22.74, up 3.04% [1] - Shuiyang Co., Ltd. (300740) at 20.43, up 2.82% [1] - Jiaheng Jiahua (300955) saw a significant decline, closing at 35.66, down 5.01% [2] - Marubi Biotechnology (603983) also fell, closing at 34.53, down 4.16% [2] Trading Volume and Capital Flow - The cosmetics sector had a net outflow of 131 million yuan from main funds, while retail investors saw a net inflow of 214 million yuan [2] - The trading volume for Qingsong Co., Ltd. was 329,200 shares, with a transaction value of 23.5 million yuan [1] - Jiaheng Jiahua had a trading volume of 50,300 shares, with a transaction value of 183 million yuan [2] Capital Flow Analysis - Shanghai Jahwa (600315) had a net inflow of 11.76 million yuan from main funds, but a net outflow of 23.52 million yuan from retail investors [3] - Other companies like Lafang Jiahua and Qingsong Co., Ltd. also experienced mixed capital flows, with retail investors showing some interest despite overall outflows from main and speculative funds [3]

Core Insights - Marubi Biotechnology (603983.SH) reported its Q3 2025 results, revealing that 12 institutional investors hold a total of 28.2179 million A-shares, accounting for 7.04% of the company's total share capital [1] - The top ten institutional investors collectively hold 6.95% of the shares, with a decrease of 0.69 percentage points compared to the previous quarter [1] Institutional Holdings - The number of institutional investors holding Marubi's A-shares is 12, with a total holding of 28.2179 million shares [1] - The top ten institutional investors include various funds and banks, with the largest being Kaishi Fund and several others from major banks [1] - The proportion of shares held by the top ten institutional investors has decreased by 0.69 percentage points from the last quarter [1] Public Fund Activity - Two public funds increased their holdings, namely ICBC New Generation Consumption Mixed and ICBC Consumption Service Mixed A, with an increase ratio of 0.14% [2] - Four public funds reduced their holdings, including Fuquan Value Creation Mixed A and Fuquan Quality Life Mixed A, with a decrease ratio of 0.42% [2] - One new public fund was disclosed, Green Hongjing Bond A, while 143 public funds were not disclosed this quarter [2] Social Security and Pension Funds - One social security fund, the National Social Security Fund 111 Combination, reduced its holdings slightly [2] - One pension fund, the Basic Pension Insurance Fund 16032 Combination, increased its holdings by 0.5% [2]

Core Insights - The company, Guangdong Marubi Biotechnology Co., Ltd., reported a robust growth in profitability for the third quarter of 2025, with significant acceleration in growth momentum [1] Financial Performance - From January to September 2025, the company achieved a net profit attributable to shareholders of 244 million yuan, maintaining steady growth despite a high base from the previous year [1] - The third quarter net profit attributable to shareholders reached 69.4816 million yuan, with a year-on-year growth rate of 11.59%, indicating a notable improvement compared to the cumulative growth rate for the first three quarters [1] - Basic earnings per share for the third quarter were 0.18 yuan, reflecting a year-on-year increase of 12.5%, which outpaced the net profit growth rate, showcasing the company's ability to enhance shareholder value [1] Growth Momentum - The company not only maintained stable profit levels in the first three quarters of 2025 but also demonstrated strong growth momentum in both profit and earnings per share, with both metrics exceeding 10% year-on-year growth in the third quarter [1]

Core Insights - The company reported a revenue of 2.45 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 22.51% [1] - The net profit attributable to the parent company reached 244 million yuan, with R&D expenses amounting to 62.79 million yuan [1] - The net cash flow from operating activities significantly increased by 132.19% year-on-year, totaling 159 million yuan, indicating improved cash flow adequacy [1] Company Developments - In Q3 2025, the company submitted 32 patent applications and played a key role in formulating 4 standards, while also publishing 2 group standards, focusing on advanced technology areas such as collagen restructuring and active substance detection [1] - The company was awarded the qualification for the Guangdong Provincial Engineering Research Center for Recombinant Functional Proteins, marking a significant recognition following the establishment of the "National Recombinant Functional Protein Technology Research Center" in 2024 [1] - In September, the company received official recognition as a provincial-level postdoctoral innovation practice base, enhancing its capability in talent cultivation in the biotechnology field and promoting collaboration between industry and academia [1]

Group 1: China National Offshore Oil Corporation (CNOOC) - CNOOC reported a net profit of 101.97 billion yuan for the first three quarters of 2025, a year-on-year decrease of 12.6% [1][2] - The company's operating income for the third quarter was 104.89 billion yuan, an increase of 5.7% year-on-year, while the net profit attributable to shareholders was 32.44 billion yuan, down 12.2% [1][2] - CNOOC's oil and gas net production reached 578.3 million barrels of oil equivalent in the first three quarters, a year-on-year increase of 6.7% [2] Group 2: BYD - BYD's net profit for the first three quarters of 2025 was 233.33 billion yuan, a decrease of 7.55% year-on-year [4][5] - The company's operating income for the third quarter was 1949.85 billion yuan, down 3.05% year-on-year, with a net profit of 78.23 billion yuan, a decline of 32.60% [4][5] Group 3: Industrial and Commercial Bank of China (ICBC) - ICBC reported a net profit of 269.91 billion yuan for the first three quarters of 2025, a year-on-year increase of 0.33% [6][7] - The bank's operating income for the third quarter was 212.93 billion yuan, up 3.41% year-on-year, with a net profit of 101.80 billion yuan, an increase of 3.29% [6][7] Group 4: China Construction Bank (CCB) - CCB's net profit for the first three quarters of 2025 was 257.36 billion yuan, a year-on-year increase of 0.62% [9][10] - The bank's operating income for the third quarter was 179.43 billion yuan, down 1.98% year-on-year, while the net profit was 95.28 billion yuan, an increase of 4.19% [9][10] Group 5: Agricultural Bank of China (ABC) - ABC reported a net profit of 220.86 billion yuan for the first three quarters of 2025, a year-on-year increase of 3.03% [14][15] - The bank's operating income for the third quarter was 1809.39 billion yuan, up 4.36% year-on-year, with a net profit of 813.49 billion yuan, an increase of 3.66% [14][15] Group 6: Ping An Insurance - Ping An Insurance's net profit for the first three quarters of 2025 was 147.79 billion yuan, a year-on-year increase of 41.01% [16][17] - The company's operating income for the third quarter was 353.27 billion yuan, down 11.48% year-on-year, with a net profit of 42.49 billion yuan, a decline of 55.98% [16][17] Group 7: Luxshare Precision - Luxshare Precision reported a net profit of 115.18 billion yuan for the first three quarters of 2025, a year-on-year increase of 26.92% [18][19] - The company's operating income for the third quarter was 964.11 billion yuan, up 31.03% year-on-year [18][19] Group 8: GF Securities - GF Securities achieved a net profit of 109.34 billion yuan for the first three quarters of 2025, a year-on-year increase of 61.64% [20][21] - The company's operating income for the third quarter was 107.66 billion yuan, up 51.82% year-on-year [20][21] Group 9: China Southern Airlines - China Southern Airlines reported a net profit of 18.70 billion yuan for the first three quarters of 2025, a year-on-year increase of 37.31% [22][23] - The company's operating income for the third quarter was 490.69 billion yuan, up 0.90% year-on-year, while the net profit was 36.76 billion yuan, down 11.31% [22][23] Group 10: China Galaxy Securities - China Galaxy Securities reported a net profit of 109.68 billion yuan for the first three quarters of 2025, a year-on-year increase of 57.51% [35][36] - The company's operating income for the third quarter was 90.04 billion yuan, up 55.94% year-on-year [35][36]

一、前期会计差错更正的原因 近期，公司收到中国证券监督管理委员会广东监管局下发的行政监管措施决 定书〔2025〕119 号（以下简称"决定书")，决定书指出公司财务核算不规范， 具体内容详见公司同日披露于上海证券交易所网站的《关于收到中国证券监督管 理委员会广东监管局行政监管措施决定书的公告》（公告编号：2025-032）。根据 决定书所认定的情况，公司对财务报告数据进行了严格自查，并针对决定书中涉 及的事项进行整改工作。根据《企业会计准则第 28 号—会计政策、会计估计变 更和差错更正》及中国证监会《公开发行证券的公司信息披露编报规则第 19 号 —财务信息的更正及相关披露》的有关规定和要求，结合自查情况，并基于审慎 性原则，对上述问题产生的前期会计差错进行更正调整。 证券代码：603983 证券简称：丸美生物 公告编号：2025-033 广东丸美生物技术股份有限公司 关于前期会计差错更正的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 广东丸美生物技术股份有限公司（以下简称"公司"）于 2025 年 10 月 ...